First Prospective Clinical Utility Trial Using Comprehensive Liquid Biopsy To Guide Metastatic Cancer Patients To Molecularly Matched Therapies Demonstrates Comparable Results To Tissue-Based Testing

Guardant Health and Samsung Medical Center (Sungkyunkwan University School of Medicine, Korea) announced today the results of the first prospective clinical trial using a comprehensive liquid biopsy test as the sole diagnostic tool used by doctors to guide metastatic cancer patients to matched therapy across multiple cancers.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news